Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 916-925

  Mendoza Ferri, Maria G ^a   Hartinger, Christian G ^a,b   Mendoza, Marco A ^a,c   Groessl, Michael ^a   Egger, Alexander E ^a   Eichinger, Rene E ^a   Mangrum, John B ^d   Farrell, Nicholas P ^d   Maruszak, Magdalena ^e   Bednarski, Patrick J ^e   Klein, Franz ^a   Jakupec, Michael A ^a   Nazarov, Alexey A ^a,b   Severin, Kay ^b   Keppler, Bernhard K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b EPFL   (Switzerland)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANE DERIVATIVE; ANTINEOPLASTIC AGENT; BBR 3464; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CISPLATIN; DNA; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; NUCLEIC ACID BASE; OXALIPLATIN; OXOPLATIN; PLASMID DNA; PLATINUM DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PRODRUG; RUTHENIUM DERIVATIVE; TRANSFERRIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL LINE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA BINDING; DRUG HYDROLYSIS; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPOPHILICITY; PKA; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROLYSIS; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; LIGANDS; ORGANOMETALLIC COMPOUNDS; PLATINUM COMPOUNDS; RUTHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERRIN;

EID: 64349103602     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8013234     Document Type: Article

References (54)

1. Galanski, M.; Jakupec, M. A.; Keppler, B. K. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem. 2005, 12, 2075-2094.
2. Zhang, C. X.; Lippard, S. J. New metal complexes as potential therapeutics. Curr. Ovin. Chem. Biol. 2003, 7, 481-489.
3. Hartinger, C. G.; Dyson, P. J. Bioorganometallic chemistry -from teaching paradigms to medicinal applications. Chem. Soc. Rev. 2009, DOI:10.1039/B707077M.
4. van Zutphen, S.; Reedijk, J. Targeting platinum anti-tumour drugs: overview of strategies employed to reduce systemic toxicity. Coord. Chem. Rev. 2005, 249, 2845-2853.
5. Haag, R.; Kratz, F. Polymer therapeutics: concepts and applications. Angew. Chem., Int. Ed. 2006, 45, 1198-1215.
6. Hartinger, C. G.; Nazarov, A. A.; Ashraf, S. M.; Dyson, P. J.; Keppler, B. K. Carbohydrate-metal complexes and their potential as anticancer agents. Curr. Med. Chem. 2008, 15, 2574-2591.
7. Kasparkova, J.; Novakova, O.; Vrana, O.; Farrell, N.; Brabec, V. Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking. Biochemistry 1999, 38, 10997-11005.
8. Manzotti, C.; Pratesi, G.; Menta, E.; Domenico, R. D.; Cavalletti, E.; Fiebig, H. H.; Kelland, L. R.; Farrell, N.; Polizzi, D.; Supino, R.; Pezzoni, G.; Zunino, F. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin. Cancer Res. 2000, 6, 2626-2634.
9. Jodrell, D. I.; Evans, T. R. J.; Steward, W.; Cameron, D.; Prendiville, J.; Aschele, C.; Noberasco, C.; Lind, M.; Carmichael, J.; Dobbs, N.; Camboni, G.; Gatti, B.; De Braud, F. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur. J. Cancer 2004, 40, 1872-1877.
10. Kostova, I. Platinum complexes as anticancer agents. Recent Pat. Anti-Cancer Drug Discovery 2006, 1, 1-22.
11. Hensing, T. A.; Hanna, N. H.; Gillenwater, H. H.; Camboni, M. G.; Allievi, C.; Socinski, M. A. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anti-Cancer Drugs 2006, 17, 697-704.
12. Rademaker-Lakhai, J. M.; Van Den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthen- ate, a novel ruthenium anticancer agent. Clin. Cancer Res. 2004, 10, 3717-3727.
13. Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From bench to bedside-preclinical and early clinical development of the anticancer agent indazolium trans- [tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem. 2006, 100, 891-904.
14. 2] and serum proteins. J. Inorg. Biochem. 2004, 98, 1135-1142.
15. Timerbaev, A. R.; Aleksenko, K. S.; Polec-Pawlak, K.; Ruzik, R.; Semenova, O.; Hartinger, C. G.; Oszwaldowski, S.; Galanski, M.; Jarosz, M.; Keppler, B. K. Platinum metallodrug-protein binding studies by capillary electrophoresis- inductively coupled plasma- mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis 2004, 25, 1988-1995.
16. Hartinger, C. G.; Hann, S.; Koellensperger, G.; Sulyok, M.; Grossl; Timerbaev, A. R.; Rudnev, A. V.; Stingeder, G.; Keppler, B. K. Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins-significance for the patient. Int. J. Clin. Pharmacol. Ther. 2005, 43, 583-585.
17. Sulyok, M.; Hann, S.; Hartinger, C. G.; Keppler, B. K.; Stingeder, G.; Koellensperger, G. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J. Anal. At. Spectrom. 2005, 20, 856-863.
18. Timerbaev, A. R.; Rudnev, A. V.; Semenova, O.; Hartinger, C. G.; Keppler, B. K. Comparative binding of antitumor indazolium [trans- tetrachlorobis(1 H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis. Anal. Biochem. 2005, 341, 326-333.
19. Polec-Pawlak, K.; Abramski, J. K.; Semenova, O.; Hartinger, C. G.; Timerbaev, A. R.; Keppler, B. K.; Jarosz, M. Platinum group metallodrug- protein binding studies by capillary electrophoresis- inductively coupled plasma-mass spectrometry: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. Electrophoresis 2006, 27, 1128-1135.
20. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem. Rev. 2006, 106, 2224-2248.
21. 4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4- triazole): aquation, redox properties, protein binding, and antiproliferative activity. J. Med. Chem. 2007, 50, 2185-2193.
22. Jakupec, M. A.; Reisner, E.; Eichinger, A.; Pongratz, M.; Arion, V. B.; Galanski, M.; Hartinger, C. G.; Keppler, B. K. Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J. Med. Chem. 2005, 48, 2831-2837.
23. Schluga, P.; Hartinger, C. G.; Egger, A.; Reisner, E.; Galanski, M.; Jakupec, M. A.; Keppler, B. K. Redox behavior of tumor inhibiting ruhenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans. 2006, 1796-1802.
24. Clarke, M. J.; Zhu, F.; Frasca, D. R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev. 1999, 99, 2511-2533.
25. Clarke, M. J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev. 2003, 236, 209-233.
26. Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organo- metallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. Commun. 2005, 4764, 4776.
27. Ang, W. H.; Dyson, P. J. Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem. 2006, 4003-4018.
28. Allardyce, C. S.; Dyson, P. J. Medicinal properties of organometallic compounds. Top. Organomet. Chem. 2006, 17, 177-210.
29. Chatterjee, S.; Kundu, S.; Bhattacharyya, A.; Hartinger, C. G.; Dyson, P. J. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J. Biol. Inorg. Chem. 2008, 13, 1149-1155.
30. Huxham, L. A.; Cheu, E. L. S.; Patrick, B. O.; James, B. R. The synthesis, structural characterization, and in vitro anti-cancer activity of chloro(p-cymene) complexes of ruthenium(II) containing a disulfoxide ligand. Inorg. Chim. Acta 2003, 352, 238-246.
31. Bergamo, A.; Stocco, G.; Gava, B.; Cocchietto, M.; Alessio, E.; Serli, B.; Iengo, E.; Sava, G. Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J. Pharmacol. Exp. Ther. 2003, 305, 725-732.
32. Hotze, A. C. G.; Kariuki, B. M.; Hannon, M. J. Dinuclear double-stranded metallosupramolecular ruthenium complexes: potential anticancer drugs. Angew. Chem., Int. Ed. 2006, 45, 4839-4842.
33. Therrien, B.; Ang, W. H.; Cherioux, F.; Vieille-Petit, L.; Juillerat-Jeanneret, L.; Suess-Fink, G.; Dyson, P. J. Remarkable anticancer activity of triruthenium-arene clusters compared to tetrarutheniumarene clusters. J. Cluster Sci. 2007, 18, 741-752.
34. Schmitt, F.; Govindaswamy, P.; Suess-Fink, G.; Ang, W. H.; Dyson, P. J.; Juillerat-Jeanneret, L.; Therrien, B. Ruthenium porphyrin compounds for photodynamic therapy of cancer. J. Med. Chem. 2008, 51, 1811-1816.
35. Auzias, M.; Therrien, B.; Suess-Fink, G.; Stepnicka, P.; Ang, W. H.; Dyson, P. J. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity. Inorg. Chem. 2008, 47, 578-583.
36. 6+: a Trojan horse for cancer cells. Angew. Chem., Int. Ed. 2008, 47, 3773-3776.
37. Mendoza-Ferri, M. G.; Hartinger, C. G.; Eichinger, R. E.; Stolyarova, N.; Severin, K.; Jakupec, M. A.; Nazarov, A. A.; Keppler, B. K. Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds. Organometallics 2008, 27, 2405-2407.
38. Mendoza-Ferri, M. G.; Hartinger, C. G.; Nazarov, A. A.; Kandioller, W.; Severin, K.; Keppler, B. K. Modifying the structure of dinuclear ruthenium complexes with antitumor activity. Appl. Organomet. Chem. 2008, 22, 326-332.
39. Peacock, A. F. A.; Melchart, M.; Deeth, R. J.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Osmium(II) and ruthenium(II) arene maltolato complexes rapid hydrolysis and nucleobase binding. Chem. Eur. J 2007, 13, 2601-2613.
40. OECD Guidelines for Testing of Chemicals; Organisation for Economic Co-operation and Development: Paris, 1995; No. 107.
41. Gomme, P. T.; McCann, K. B.; Bertolini, J. Transferrin: structure, function and potential therapeutic actions. Drug Discovery Today 2005, 10, 267-273.
42. Hartinger, C. G.; Ang, W. H.; Casini, A.; Messori, L.; Keppler, B. K.; Dyson, P. J. Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. J. Anal. At. Spectrom 2007, 22, 960-967.
43. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Moneti, G.; Pieraccini, G. Exploring metallodrug-protein interactions by ESI mass spectrometry: the reaction of anticancer platinum drugs with horse heart cytochrome c. ChemMedChem 2006, 1, 413-417.
44. Feng, R.; Konishi, Y.; Bell, A. W. High accuracy molecular weight determination and variation characterization of proteins up to 80 ku by ionspray mass spectrometry. J. Am. Soc. Mass Spectrom. 1991, 2, 387-401.
45. Swiss Institute of Bioinformatics ExPASy Proteomics Server Basel, Switzerland. http://www.expasy.org/, 2003.
46. Dorcier, A.; Hartinger, C. G.; Scopelliti, R.; Fish, R. H.; Keppler, B. K.; Dyson, P. J. Studies on the reactivity of organometallic Ru-, Rh-and Os-pta complexes towards DNA model compounds. J. Inorg. Biochem. 2008, 102, 1066-1076.
47. Novakova, O.; Nazarov, A. A.; Hartinger, C. G.; Keppler, B. K.; Brabec, V. DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media. Biochem. Pharmacol. 2009, doi:10.1016/j.bcp.2008.1010.1021.
48. 3)Cl. Eur. J. Med. Chem. 2004, 39, 947-958.
49. Bennett, M. A.; Huang, T. N.; Matheson, T. W.; Smith, A. K. Hexamethylbenzene)ruthenium complexes. Inorg. Synth. 1982, 21, 74-78.
50. Harris, R. L. N. Potential wool growth inhibitors. Synthesis of DL-α-amino-β-(5-hydroxy-4-oxo-3,4-dihydropyrimidin-2-yl)propionic acid, a pyrimidine analog ofmimosine. Aust. J. Chem. 1976, 1335-1339.
51. Lang, R.; Polborn, K.; Severin, T.; Severin, K. Halfsandwich complexes of ruthenium(II), rhodium(III) and iridium(III) with N- substituted 3-hydroxy-2-methyl-4-pyridone ligands. Inorg. Chim. Acta 1999, 294, 62-67.
52. 2O. Biochemistry 2004, 98, 161-166.
53. Birnboim, H. C.; Doly, J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 1979, 7, 1513-1523.
54. Bracht, K.; Boubakari; Grünert, R.; Bednarski, P. J. Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data. Anti-Cancer Drugs 2006, 17, 41-51.